Clinical Trial Results
ENSPRYNG reduced the risk of relapse. More AQP4-IgG(+) adult patients were relapse-free at about 2 years (96 weeks) with ENSPRYNG than with placebo.
Do not take ENSPRYNG if you:
What is the most important information I should know about ENSPRYNG?
ENSPRYNG may cause serious side effects including:
Infections. ENSPRYNG can increase your risk of serious infections, some of which can be life-threatening. Talk to your healthcare provider if you are being treated for an infection, or call them right away if you think you have signs of an infection, with or without a fever, such as:
Your healthcare provider will check if you have an infection and treat it if needed before you start or continue to take ENSPRYNG.
For more details, see the continued Important Safety Information below.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.